EGFR and lung adenocarcinoma: To confirm the impact of ordering bias, we compared the detection rates of KRASG12C- and EGFR-activating mutations in lung adenocarcinoma among patients included in this study, newly diagnosed patients from the Noninvasive versus Invasive Lung Evaluation (NILE) study (14), and primarily treatment-naive tissues from The Cancer Genome Atlas (TCGA; 22; Appendix Fig A1).